TRANSCEND is a protein Vector to shuttle existing therapeutic drugs across the Blood-Brain Barrier.
In November 2010 Bioasis sponsored a research agreement with the National Research Council of Canada to evaluate the ability of biOasis' compounds to cross the blood-brain barrier using real time-domain in vivo optical imaging.
Prior research studies have revealed that Transcend could be conjugated with therapeutic molecules to act as a shuttle that could essentially piggy-back drugs across the Blood-Brian Barrier to deliver these therapies into the cellular level of the brain. This would represent a major break through in the treatment of Central Nervous System diseases that has heretofore been hampered by the inability to deliver drug therapies through the Blood Brain Barrier and "into the parenchyma" ~ into the cellular level of the brain.
In January 2011, the National Research Council confirmed through a fluorescence imaging study that Transcend can shuttle compounds across the blood-brain barrier. View florescence imaging slides.
|